Mutations of the p53 tumor-suppressor gene are the most frequent genetic abnormality in soft tissue sarcomas. Because these rare tumors also respond poorly to standard chemotherapy and bear a 50% 5-year mortality rate, we investigated the possible therapeutic benefits of p53 gene restoration in sarcomas. We constructed Ad5p53, which is an E1A-deleted, replication-deficient adenovirus expressing a cytomegalovirus promoter-driven wild-type p53 cDNA with a Flag sequence tag. SKLMS-1 human leiomyosarcoma cells containing a mis-sense p53 point mutation were effectively transduced with Ad5p53. Increasing levels of Flag-p53 protein, as well as dose-dependent p21
G ene-based treatment for human cancers is founded on the concept that functionally defective genes contribute to, if not directly cause, the malignant phenotype. 1 Over the preceding years, several strategies targeting cancer have evolved to administer therapeutic genes that inactivate oncogenes, restore tumor-suppressor genes, and enhance the native immune response. 2, 3 A number of investigations have focused on p53 gene therapy, aiming to restore the important tumor-suppressor functions of this molecule in cancer cells with p53 gene abnormalities. 3 The initial preclinical studies demonstrated suppressed tumor cell growth and reduced tumorigenicity in nude mice in a number of different tumor cell types stably transduced with wild-type (wt) p53. 4 -8 Some investigations have further advanced p53 gene therapy to an evaluation phase in clinical trials for several human cancers, including lung, head and neck, and colorectal cancer. 2 The growth-regulatory functions of the p53 gene are relevant to human soft tissue sarcomas, 30 -65% of which harbor a p53 mutation. 9, 10 In contrast to other tumors in which p53 biology has been studied, sarcomas are an extremely rare and histologically diverse group of human cancers. Despite multidisciplinary treatment combining surgery, radiation therapy, and chemotherapy, the overall prognosis for sarcoma patients remains poor: only 30% of patients respond to the major, doxorubicin-based chemotherapy regimens, and the 5-year mortality rate is 50%. 11 Perhaps because of the rarity of this disease, advances in new, more effective treatments have been slow, particularly in the area of gene therapy. There are limited preclinical studies addressing p53 restorative therapy in sarcomas, [12] [13] [14] and to our knowledge, no currently active clinical trials are specifically aimed at incorporating gene therapy for this malignancy. 2, 3 In this study, the therapeutic efficiency of p53 gene restoration in sarcomas was investigated by treating mice bearing tumors induced by subcutaneous injection of the SKLMS-1 human leiomyosarcoma cells, which contain mutant p53, with an adenoviral-mediated wt p53 gene delivery system such as could be applied in clinical treatment. Previously, we have demonstrated that stable wt p53 transfectants derived from this leiomyosarcoma cell line exhibit reduced tumor growth and clonogenicity in vitro, decreased tumorigenicity in severe combined immunodeficient (SCID) mice, 15 and enhanced chemosensitivity and radiosensitivity. 16, 17 Here we report the effectiveness of using Ad5p53 in inhibiting sarcoma cell growth in vitro and in suppressing tumor growth in sarcoma-bearing mice in vivo.
MATERIALS AND METHODS

Cell lines and cell culture
The human leiomyosarcoma cell line SKLMS-1 and the human embryonic kidney cell line 293 were obtained from the American Type Culture Collection (Manassas, Va). SKLMS-1 is well-characterized and contains a known p53 mis-sense mutation at codon 245 (glycine 3 serine).
15,18 SKLMS-1 cells were maintained in Dulbecco's modified Eagle's medium/F12 medium (Life Technologies, Gaithersburg, Md) with 10% fetal bovine sera (Life Technologies) in a humidified 37°C incubator with 5% CO 2 in air. Cells were subcultured 1:3 by trypsinization upon reaching confluence. The 293 cells were also maintained in Dulbecco's modified Eagle's medium/F12 with 10% fetal bovine serum and were used for experiments at passages 35-40.
Construction of Ad5p53 vector
A p53-Flag recombinant adenovirus was designed to contain a cytomegalovirus (CMV) promoter, Flag-peptide tag, wt p53 cDNA, and human growth hormone (hGH) polyadenylation signal. It was generated by first isolating the 1.8-kb BamHIBamHI p53 cDNA fragment from the pCMV-Neo-Bam vector (kindly provided by Dr. Bert Vogelstein, Johns Hopkins Oncology Center, Baltimore, Md) and removing the 5Ј untranscribed region by NcoI partial digestion. This cDNA fragment was inserted into the pFlag-CMV-2 expression vector (Kodak Scientific Imaging Systems, New Haven, Conn) containing the CMV promoter, Flag-peptide, and hGH poly(A). The p53-Flag expression cassette was generated after SpeI and PinAI double digestion and subsequently ligated to a shuttle vector, E1sp1A (Microbix Biosystems, Ontario, Canada). The above DNA construct was cotransfected with the pJM17 plasmid, which contains the entire E1-deleted Ad5 genome, into 293 cells for homologous recombination by N- (1-[2,3-dioleoyloxy] propyl)-N,N,N-trimethylammonium methylsulfate liposomal-mediated transfection according to the manufacturer's protocol (Boehringer Mannheim, Indianapolis, Ind). The 293 cells were plated 24 hours before transfection at 60% confluency in 60-mm dishes and transfected with 11 g/60-mm dish of pJM17 and p53 shuttle vector (1:1 ratio) per 100 L of N- (1-[2,3-dioleoyloxy] propyl)-N,N,N-trimethylammonium methylsulfate liposome. After transfection, cells were fed culture media every 2-3 days until the onset of cytopathic effects. Aliquots of cell culture supernatants were collected from plates with detectable cytopathic effects and stored as candidate positive p53 adenoviral stocks, which were further characterized by restriction mapping, polymerase chain reaction (PCR), and Western blot analysis described below. A clone expressing wt p53 (Ad5p53) and a clone without the gene insert (Ad5c4) were then further amplified in 293 cells, collected by cell lysis after three freeze-thaw cycles at Ϫ80°C, purified by a CsCl gradient, and desalted in dialysis buffer (10 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.5), 1 mM MgCl 2 , 10% glycerol). Aliquots of purified virus were stored as viral stock in phosphate-buffered saline (PBS) with 10% glycerol. Viral titer was calculated from an optical density 260 reading of the viral stock solution and ranged from 1.45 ϫ 10 10 to 4.5 ϫ 10 10 plaque-forming units (PFU)/mL.
Identification of recombinant p53 adenovirus
Viral stocks derived from single 293 cell plaques were analyzed for the presence or absence of appropriate p53-Flag insert in the adenoviral vectors. DNA was extracted from viral stock samples using the QIAamp Blood and Tissue Kit (Qiagen, Chatsworth, Calif). A panel of candidate clones were subjected to restriction enzyme mapping with HindIII to verify that a product of predicted size was obtained, indicating successful DNA recombination. To check for the presence of the p53-Flag insert, PCR amplification with the primers CMV-30-S-5Ј (5Ј-AATGTCGTAATAACCCCGC-CCCGTTGACGC-3Ј) and p53-2-3Ј (5Ј-GGAACAAGAAGTG-GAGAATG-3Ј) was performed for 32 cycles at 94°C ϫ 1 minute, 56°C ϫ 1.5 minutes, and 72°C ϫ 2 minutes. PCR products were resolved on a 1% agarose gel and photographed under ultraviolet light. Finally, to check for the ability of the p53 adenovirus to induce expression of exogenous p53 protein, 293 cells were reinfected with candidate vectors at doses of up to 100 PFU/cell, and the presence of p53 in cellular protein extracts was assessed by Western blotting as described below.
In vitro growth assay SKLMS-1 cells and 293 cells were infected in culture media with Ad5p53 or control virus Ad5c4 at the following multiplicities of infection to determine transduction efficiency: 0, 10, 50, 100, and 500 PFU/cell. The cells at 80% confluency in culture were infected, and protein extracts were prepared 48 hours later for analysis of Flag protein, p53, p21 Cip1 , and actin. This information allowed for the selection of an appropriate dose for the growth rate assays. Untreated SKLMS-1 cells and SKLMS-1 cells treated with a one-time dose of 100 PFU/cell Ad5p53 or Ad5c4 in media were plated into 6-well plates at a density of 10 4 cells/well. Cells were harvested at posttreatment days 2, 4, 6, and 8 by trypsinization. Cell viability was assessed by trypan blue dye exclusion, and cell count was determined using a hemocytometer. Each timepoint for each treatment group had triplicate wells. The entire experiment was repeated three times starting from viral infection of new SKLMS-1 cultures, and data were plotted from the averages of all experiments.
Detection of p53, p21
Cip1 , and Flag proteins
Proteins were extracted from SKLMS-1 cells and 293 cells that were untreated or transduced with adenoviruses using PBSTDS lysis buffer (10 mM Na 2 HPO 4 , 155 mM NaCl, 1% Triton X-100, 3 mM sodium dodecyl sulfate, 11 mM sodium deoxycholate, 30 mM NaN 3 , 0.9 mM NaF, pH 7.25), quantified with the bicinchoninic acid protein assay (Pierce, Rockford, Ill), resolved on a 12% polyacrylamide gel (Bio-Rad, Hercules, Calif), and electroblotted onto a nitrocellulose membrane (Bio-Rad). The following primary antibodies (Abs) were used: monoclonal mouse anti-human p53 In vivo tumorigenicity assay SKLMS-1 cells were grown to confluence in vitro, harvested by trypsinization, rinsed with PBS, and resuspended in Matrigel (Becton Dickinson, Bedford, Mass). An aliquot of 5 ϫ 10 6 cells was injected subcutaneously into the flank of SCID mice, and tumors allowed to develop to 0.5 mm diameter in size. Animals then received intratumoral injections of saline (n ϭ 10), Ad5c4 (n ϭ 10), or Ad5p53 (n ϭ 10) on a schedule of 10 9 PFU in 50 L injected every other day for a total of six injections (total dose: 6 ϫ 10 9 PFU). Daily weights and tumor size measurements were obtained every 2 days from the first treatment administration. Mice were sacrificed when the tumor diameter reached 2 cm. The experiment was performed in duplicate. Tumor volume was calculated as ([a ϫ b 2 ]/2), where a represents the largest tumor diameter and b represents the smallest tumor diameter. 19 Tumor growth delay was calculated as the difference between the time required for treated tumors to reach 200 cm 3 and the time for saline-treated tumors to reach the same size.
Detection of Ad5p53 in tumor samples
Tumors were harvested 72 hours after injection with saline, Ad5c4, or Ad5p53 (6 ϫ 10 9 PFU single treatment) and rinsed in PBS; portions were preserved in 3.8% formalin and embedded in paraffin. Immunostaining was performed on 4-m tissue sections using the avidin-biotin-peroxidase method of Hse et al. 20 Briefly, tissue sections were dewaxed and dehydrated, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. The sections were then treated with normal horse sera followed by overnight incubation at 4°C with anti-p53 Ab (D01, 1/200 dilution; Novocastra Laboratories, Newcastle on Tyne, UK).
Fresh tumor tissue was used in the detection of exogenous p53 by reverse transcriptase (RT)-PCR. Tumors were treated every other day with saline, Ad5c4, or Ad5p53 at a dose of 10 9 PFU per injection for six injections total. Tumors were then harvested 3 days after the third injection and 3 and 10 days after the last injection. Total RNA was extracted from tumor tissue using RNAzol B (Tel-Test, Friendswood, Tex), and first-strain cDNA synthesis was performed with the SuperScript Preamplification System (Life Technologies). The cDNA was amplified by PCR with p53 flanking primers; cycling conditions were as described above. The PCR products were resolved on a 1.2% low-melting agarose gel. To intensify the signal from the 1.3-kb p53 insert, the 1.3-kb p53 band was isolated from the gel and melted at 45°C for 10 minutes; next, 2 L of the resulting product was used for a second PCR. The PCR conditions and primers remained the same for the second PCR, and products were resolved on a 1% agarose gel.
RESULTS
Generation of Ad5p53 virus and transduction of human sarcoma cells
The Ad5p53 virus was constructed by first generating an expression cassette that contained a CMV promoter, a Flag tag, human wt p53 cDNA, and a hGH polyadenylation signal (Fig 1A) 
. PCR amplification of a region extending from the 5Ј Flag end to the 3Ј wt p53 cDNA yielded the expected 1.3-kb product from the Ad5p53 virus and the adenovirus clone 10 but not from the Ad5c4 virus ( Fig  1B) . To further confirm that Ad5p53 infection led to the expression of Flag-tagged p53 protein, Western blot analysis was performed on protein samples prepared from the 293 cell culture infected with this recombinant virus clone, as well as on samples from 293 cells infected with the adenoviruses clone 10 and Ad5c4. Figure 1C shows the presence of Flag-tagged p53 proteins in 293 cells infected with Ad5p53 using both anti-Flag and anti-p53 Abs. Although the 1.3-kb p53 cDNA insert can be detected in the adenovirus clone 10, expression of the Flag-tagged p53 protein was undetectable and clone 10 was not used for further investigation. Ad5c4 was an empty adenoviral vector construct with a deleted E1A region that did not integrate the 1.3-kb p53 cDNA insert and did not express the Flag-tagged p53 protein. Therefore, this virus was used as a viral control in all subsequent experiments.
To assess the ability of Ad5p53 virus to transduce SKLMS-1 human leiomyosarcoma cells and to express the Flag-tagged p53 protein in these cells, Western blot analysis was performed on protein extracts from SKLMS-1 cells collected 48 hours after infection with 0 -500 PFU/cell Ad5p53. Figure 2 shows that Ad5p53 virus effectively transduced the sarcoma cells, with exogenous Flag-tagged p53 proteins present at viral doses of 50 PFU/cell and increasing with higher doses. In addition, Ad5p53 caused a dose-dependent induction of p21
Cip1 in SKLMS-1 cells, indicating that the exogenous p53 protein is functionally active in regulating its downstream target genes, such as p21
Cip1 . The expression of Flag-tagged p53 proteins was lower in SKLMS-1 cells than in 293 cells, which are specifically engineered to contain the adenoviral E1 region and thus allow efficient viral replication; Ad5p53 infection in 293 cells led to peak p53 and Flag protein expression already at the 10 PFU/cell dose, although there was an absence of p21 Cip1 induction, possibly because other genetic alterations in these cells may interfere with p53's function as a transcriptional activator for p21
Cip1 . These results confirmed that the Ad5p53 virus could be used to infect human SKLMS-1 sarcoma cells and deliver multiple copies of the p53 gene, which leads to active translation of a functionally competent p53 protein.
Effect of exogenous p53 on sarcoma growth in vitro
To determine whether virally delivered p53 can exert growth-regulatory effects on SKLMS-1 cells, an in vitro growth rate assay was performed using untreated, Ad5p53-treated, or Ad5c4-treated SKLMS-1 cells. A one-time dose of 100 PFU/cell Ad5p53 or Ad5c4 was used to maximize gene transfer efficiency and minimize toxicity. Triplicate sets of untreated and treated cells were analyzed every other day for 8 days for cell viability and cell count, and the experiment was repeated three times. Ad5p53-treated SKLMS-1 cells showed 40 -60% growth inhibition at posttreatment days 4, 6, and 8, relative to untreated and Ad5c4-infected cells (P Ͻ .05, Student's t test; Fig 3) . The Ad5c4-treated cells displayed a growth rate similar to that of untreated cells.
Cell viability was assessed by trypan blue dye exclusion and was found to be in the range of 93-100% for all treatment groups during the entire culture period. This suggested that the reduced growth rate might reflect cells/well in 6-well plates. Cell viability ranged from 93% to 100% at all timepoints in each of the treatment groups. The curves represent the combined data of three experiments. The difference in growth between Ad5p53-treated cells versus both untreated and viral control-treated cells was statistically significant (P Ͻ .05, Student's t test) for days 4 -8. changes in cell proliferation rather than cell toxicity. In addition, no significant induction of apoptosis was detected for all treatment groups under this culture condition. Overall, these results indicate that the virally delivered p53 gene significantly inhibits the in vitro growth rate of SKLMS-1 sarcoma cells.
Inhibition of sarcoma tumorigenicity by Ad5p53 in vivo
To examine whether the Ad5p53 virus may be used as a p53 gene therapy agent for p53 mutation-bearing human soft tissue sarcomas in a living host, we first developed a tumor-bearing mouse model by injecting SCID mice subcutaneously with SKLMS-1 cells. We subsequently treated these mice with an intratumoral injection of saline, Ad5p53, or Ad5c4 when the SKLMS-1 tumor nodules reached a size of 0.5 cm in diameter. Each mouse received six injections either of 10 9 PFU virus in 50 L saline or of saline alone, administered every 48 hours for 12 days. The total viral dose was 6 ϫ 10 9 PFU/mouse. The tumor growth rate for each of the treatment groups is depicted in Figure 4A . The tumors were measured at intervals evident on the graph beginning with the day of initial treatment and continuing until they reached maximum allowable size. Ad5p53 treatment of SKLMS-1 tumors significantly reduced tumor growth, compared with both saline-and Ad5c4-treated tumors (P Ͻ .05, Student's t test). At day 40, Ad5p53 tumors were 80% smaller in size than salinetreated tumors and 54% smaller than control-vector treated tumors. The tumor growth delay to reach 200 mm 3 was 35 days; whereas the saline-and control vector-treated tumors enlarged to this volume within 5 days of initial injection, nearly 40% of Ad5p53 tumors completely regressed, and the remainder slowly grew to this size by day 40 postinjection (Fig 4B) .
Tumors harvested from SCID mice after treatment were analyzed for mRNA expression from the exogenous p53 gene and to determine the histological characteristics of the p53 treatment response. As illustrated in Figure 5A , Flag-p53 mRNA derived from Ad5p53 was demonstrable by RT-PCR in the tumors treated with Ad5p53, implying that the expression of exogenous wt p53 RNA occurred after gene delivery in vivo, as it did in vitro. Figure 5B shows SKLMS-1 tumor sections immunohistochemically stained for p53 protein. Only tumor sections from the Ad5p53-treated mice displayed decreased cellularity within the nodule and p53 staining in the immediately adjacent normal tissues around the tumor and in the connective tissue elements within the 
DISCUSSION
In this study, we demonstrate the applicability of current gene therapy strategies to the investigation and treatment of human soft tissue sarcomas. The tumor-suppressor gene p53 is among those molecular therapies that may prove to be valuable in the clinical treatment of a number of human cancers, by restoring to tumors the growth-regulatory capacity which had been lost during the course of neoplastic transformation. 2, 5 This gene is currently being delivered via recombinant adenovirus as the main gene delivery strategy in clinical trials for lung cancer and head and neck cancers. 2 The results presented here show that adenoviral p53 therapy leads to the successful delivery of wt p53 genes into human leiomyosarcoma cells harboring mutant p53, resulting in substantial growth inhibition of sarcoma cells both in vitro and in vivo, making p53 gene therapy a plausible new treatment strategy for this malignancy.
The adenovirus used in our studies, Ad5p53, was constructed to be replication-deficient and to contain the human CMV promoter, Flag tag sequence, human wt p53 cDNA, and hGH polyadenylation signal. It is similar to previously reported p53 adenoviral gene therapy vectors, 2, 6 except that the Flag tag is fused to the N terminus of p53 cDNA. Ad5p53 mediated a dose-dependent expression of p53 protein in human SKLMS-1 leiomyosarcoma cells and led to the induction of the cell cycle regulator p21
Cip1 in vitro, demonstrating that Ad5p53 can deliver functionally potent wt p53. A single in vitro treatment of 100 PFU/cell achieved significant sarcoma growth inhibition that persisted for at least 8 days. A series of in vivo treatments by intratumoral injection of 6 ϫ 10 9 PFU likewise caused full regression of some tumor nodules and substantially retarded growth in others, which lagged in size 35 days behind the saline-and virus control-treated tumors. Thus, shortterm, exogenous p53 administration appears to be effective in diminishing the growth of sarcomas in a monolayer environment and in reducing their tumorigenicity in vivo.
A major implication of these experiments is that possible therapeutic benefits may be derived when normal, wt p53 is restored to human sarcomas. The preclinical studies reported here provide important information about growth regulation by adenoviral p53 in sarcomas. These findings, combined with earlier observations from our laboratory that p53 enhances the chemosensitivity and radiosensitivity of sarcomas, justify the investigation of Ad5p53 as a single agent or in combination with chemotherapeutic drugs or radiation for the treatment of sarcomas. Ad5p53 can further be evaluated for its effectiveness in sarcoma therapy by investigation using other sarcoma histological subtypes or delivery methods that have unique relevance to sarcoma treatment. For example, we have demonstrated previously in an animal model 21 that it is feasible to deliver genetic constructs to a tumor-bearing limb using isolated limb perfusion, a technique currently in clinical use for the treatment of advanced extremity sarcomas. The therapeutic effects of p53 gene therapy, if confirmed in such clinical studies, would have tremendous practical ramifications, because there are significantly fewer choices for the effective treatment of these rare tumors compared with other cancers. Only ϳ30% of patients respond to the most frequently used chemotherapeutic agent, doxorubicin, and the prognosis for the majority of patients is poor, as reflected in overall 5-year mortality rates, which remain close to 50%. 11 The current lack of new therapeutic choices for patients burdened by these tumors is a significant reality. It is applications such as isolated limb perfusion and the potential of combining p53 gene therapy with current multimodality treatment options that may improve the therapeutic response of sarcoma patients and their overall prognostic outlook.
